Recent Study of Boron Neutron Capture Therapy for Malignant Brain Tumor in Japan

1996 ◽  
pp. 717-724 ◽  
Author(s):  
Yoshinobu Nakagawa ◽  
Hiroshi Hatanaka
Keyword(s):  
Brain Tumor ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Malignant Brain Tumor ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

An improved neutron collimator for brain tumor irradiations in clinical boron neutron capture therapy

1996 ◽  
Vol 23 (12) ◽  
pp. 2051-2060 ◽  
Author(s):  
Hungyuan B. Liu ◽  
Dennis D. Greenberg ◽  
Jacek Capala ◽  
Floyd J. Wheeler
Keyword(s):  
Brain Tumor ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

scholarly journals The Dosimetric Impact of Shifts in Patient Positioning during Boron Neutron Capture Therapy for Brain Tumors

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Jia-Cheng Lee ◽  
Yi-Wei Chen ◽  
Keh-Shih Chuang ◽  
Fang-Yuh Hsu ◽  
Fong-In Chou ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Brain Tumors ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Patient Positioning ◽  
Planning System ◽  
Head Model ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Beam Aperture

Unlike conventional photon radiotherapy, sophisticated patient positioning tools are not available for boron neutron capture therapy (BNCT). Thus, BNCT remains vulnerable to setup errors and intra-fractional patient motion. The aim of this study was to estimate the impact of deviations in positioning on the dose administered by BNCT for brain tumors at the Tsing Hua open-pool reactor (THOR). For these studies, a simulated head model was generated based on computed tomography (CT) images of a patient with a brain tumor. A cylindrical brain tumor 3 cm in diameter and 5 cm in length was modeled at distances of 6.5 cm and 2.5 cm from the posterior scalp of this head model (T6.5 cm and T2.5 cm, respectively). Radiation doses associated with positioning errors were evaluated for each distance, including left and right shifts, superior and inferior shifts, shifts from the central axis of the beam aperture, and outward shifts from the surface of the beam aperture. Rotational and tilting effects were also evaluated. The dose prescription was 20 Gray-equivalent (Gy-Eq) to 80 % of the tumor. The treatment planning system, NCTPlan, was used to perform dose calculations. The average decreases in mean tumor dose for T6.5 cm for the 1 cm, 2 cm, and 3 cm lateral shifts composed by left, right, superior, and inferior sides, were approximately 1 %, 6 %, and 11 %, respectively, compared to the dose administered to the initial tumor position. The decreases in mean tumor dose for T6.5 cm were approximately 5 %, 11 %, and 15 % for the 1 cm, 2 cm, and 3 cm outward shifts, respectively. For a superficial tumor at T2.5cm, no significant decrease in average mean tumor dose was observed following lateral shifts of 1 cm. Rotational and tilting up to 15° did not result in significant difference to the tumor dose. Dose differences to the normal tissues as a result of the shifts in positioning were also minimal. Taken together, these data demonstrate that the mean dose administered to tumors at greater depths is potentially more vulnerable to deviations in positioning, and greater shift distances resulted in reduced mean tumor doses at the THOR. Moreover, these data provide an estimation of dose differences that are caused by setup error or intra-fractional motion during BNCT, and these may facilitate more accurate predictions of actual patient dose in future treatments.

scholarly journals Salvage Boron Neutron Capture Therapy for Malignant Brain Tumor Patients in Compliance with Emergency and Compassionate Use: Evaluation of 34 Cases in Taiwan

Biology ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 334
Author(s):  
Yi-Wei Chen ◽  
Yi-Yen Lee ◽  
Chun-Fu Lin ◽  
Po-Shen Pan ◽  
Jen-Kun Chen ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Brain Tumors ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Tumor Patients ◽  
Boron Neutron Capture ◽  
Life Threatening ◽  
The Mean ◽  
End Stage

Although boron neutron capture therapy (BNCT) is a promising treatment option for malignant brain tumors, the optimal BNCT parameters for patients with immediately life-threatening, end-stage brain tumors remain unclear. We performed BNCT on 34 patients with life-threatening, end-stage brain tumors and analyzed the relationship between survival outcomes and BNCT parameters. Before BNCT, MRI and 18F-BPA-PET analyses were conducted to identify the tumor location/distribution and the tumor-to-normal tissue uptake ratio (T/N ratio) of 18F-BPA. No severe adverse events were observed (grade ≥ 3). The objective response rate and disease control rate were 50.0% and 85.3%, respectively. The mean overall survival (OS), cancer-specific survival (CSS), and relapse-free survival (RFS) times were 7.25, 7.80, and 4.18 months, respectively. Remarkably, the mean OS, CSS, and RFS of patients who achieved a complete response were 17.66, 22.5, and 7.50 months, respectively. Kaplan–Meier analysis identified the optimal BNCT parameters and tumor characteristics of these patients, including a T/N ratio ≥ 4, tumor volume < 20 mL, mean tumor dose ≥ 25 Gy-E, MIB-1 ≤ 40, and a lower recursive partitioning analysis (RPA) class. In conclusion, for malignant brain tumor patients who have exhausted all available treatment options and who are in an immediately life-threatening condition, BNCT may be considered as a therapeutic approach to prolong survival.

Sign in / Sign up

Export Citation Format

Share Document